Literature DB >> 3778197

Role of aromatic amine acetyltransferase in human colorectal cancer.

N P Lang, D Z Chu, C F Hunter, D C Kendall, T J Flammang, F F Kadlubar.   

Abstract

Hepatic arylamine acetyltransferase phenotype has been suggested to be an important risk factor for urinary bladder carcinogenesis in individuals with known exposure to aromatic amines. This study was performed to evaluate the relative distribution of fast- and slow-acetylator phenotypes both in a population of men, 45 to 75 years of age, with a history of colorectal cancer and in a matched control group. Acetyltransferase activity was determined by administration of sulfamethazine and by subsequent analysis of blood and urine samples for N-acetylsulfamethazine and sulfamethazine using high-pressure liquid chromatography. The control group was composed of 28 slow-, two intermediate-, and 11 fast-acetylator individuals, while the group of patients with a history of cancer consisted of 20 slow-, three intermediate-, and 20 fast-acetylator phenotypes. This higher relative proportion of fast acetylators in the patients with a cancer history was highly significant and is consistent with the hypothesis that aromatic amines could play a role in the etiology of human colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3778197     DOI: 10.1001/archsurg.121.11.1259

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  16 in total

1.  N-Acetyltransferase polymorphism and human cancer risk.

Authors:  X Yang; T Takeshita; K Morimoto
Journal:  Environ Health Prev Med       Date:  2000-01       Impact factor: 3.674

Review 2.  Human colonocyte detoxification.

Authors:  W E Roediger; W Babidge
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

3.  N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions.

Authors:  A L Hubbard; D J Harrison; C Moyes; A H Wyllie; C Cunningham; E Mannion; C A Smith
Journal:  Gut       Date:  1997-08       Impact factor: 23.059

4.  Vitamin C inhibited DNA adduct formation and arylamine N-acetyltransferase activity and gene expression in rat glial tumor cells.

Authors:  C F Hung; K H Lu
Journal:  Neurochem Res       Date:  2001-10       Impact factor: 3.996

Review 5.  Interplay between heterocyclic amines in cooked meat and metabolic phenotype in the etiology of colon cancer.

Authors:  P Vineis; A McMichael
Journal:  Cancer Causes Control       Date:  1996-07       Impact factor: 2.506

6.  Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases.

Authors:  D W Hein; T D Rustan; R J Ferguson; M A Doll; K Gray
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

7.  Berberine inhibited arylamine N-acetyltransferase activity and gene expression and DNA adduct formation in human malignant astrocytoma (G9T/VGH) and brain glioblastoma multiforms (GBM 8401) cells.

Authors:  D Y Wang; C C Yeh; J H Lee; C F Hung; J G Chung
Journal:  Neurochem Res       Date:  2002-09       Impact factor: 3.996

8.  Caffeine phenotyping of cytochrome P4501A2, N-acetyltransferase, and xanthine oxidase in patients with familial adenomatous polyposis.

Authors:  A D Spigelman; K C Farmer; S Oliver; K P Nugent; P N Bennett; L J Notarianni; P Dobrocky; R K Phillips
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

9.  Human acetylator genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol.

Authors:  J W Rodriguez; W G Kirlin; R J Ferguson; M A Doll; K Gray; T D Rustan; M E Lee; K Kemp; P Urso; D W Hein
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

10.  Absence of association between N-acetyltransferase 2 acetylator status and colorectal cancer susceptibility: based on evidence from 40 studies.

Authors:  Lou qian Zhang; Jian nong Zhou; Jun Wang; Guo dong Liang; Jing ying Li; Yi dan Zhu; Yun tao Su
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.